Stereotactic Body Radiation Therapy for Liver Cancer
Author Information
Author(s): Choi Byung Ock, Choi Ihl Bohng, Jang Hong Seok, Kang Young Nam, Jang Ji Sun, Bae Si Hyun, Yoon Seung Kew, Chai Gyu Young, Kang Ki Mun
Primary Institution: The Catholic University of Korea, School of Medicine
Hypothesis
The study aims to evaluate the efficacy of stereotactic body radiation therapy (SBRT) for small non-resectable hepatocellular carcinoma (HCC) and SBRT combined with transarterial chemoembolization (TACE) for advanced HCC with portal vein tumor thrombosis (PVTT).
Conclusion
SBRT for small HCC and SBRT combined with TACE for advanced HCC with PVTT are effective treatments with minimal side effects.
Supporting Evidence
- The overall response rate was 71.9%, with 82.6% for small HCC and 44.4% for advanced HCC with PVTT.
- The median survival for small HCC patients was 12 months, while it was 8 months for advanced HCC with PVTT.
- No patients experienced Grade 4 toxicity.
Takeaway
Doctors used a special type of radiation therapy to treat liver cancer, and it worked well for many patients without causing serious problems.
Methodology
The study involved 31 patients treated with SBRT for 32 HCC lesions, with some receiving additional TACE.
Limitations
The study is retrospective and has a small sample size.
Participant Demographics
The median age of participants was 59 years, with a predominance of males.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website